Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MATINS: FP-1305 (Bexmarilimab) in Advanced Solid Tumors
NCT03733990Phase 2Completed
- Sponsor
- Faron Pharmaceuticals
- Start
- Dec 2018
- Primary completion
- Sep 2023
- Modality
- Monoclonal Antibodies
- Countries
- 6
01
Overview
A Phase 2 trial of bexmarilimab in hepatocellular carcinoma (HCC), gallbladder cancer, cholangiocarcinoma (CCA), colorectal adenocarcinoma, ovarian cancer, sponsored by Faron Pharmaceuticals. Started Dec 2018; status: completed.
02
Drugs
bexmarilimab
03
Conditions
hepatocellular carcinoma (HCC)gallbladder cancercholangiocarcinoma (CCA)colorectal adenocarcinomaovarian cancer
Beyond the preview
Go deeper on NCT03733990.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03733990.